Literature DB >> 14559838

Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression.

Deanna Grote1, Roberto Cattaneo, Adele K Fielding.   

Abstract

To investigate the contribution of a neutrophil response to the oncolytic effect of replicating attenuated measles virus (MV), MVs expressing murine granulocyte macrophage colony-stimulating factor (GM-CSF) were generated. The growth characteristics and kinetics of GM-CSF production of these viruses were characterized in vitro. Their biological effects were characterized in mice transgenic for the MV receptor CD46. The oncolytic efficacy of MV GM-CSF was then compared with that of a parental MV and a control, UV-irradiated MV using a human lymphoid tumor model in immunodeficient mice. Intratumoral injection of MV resulted in significant tumor regression or slowing of progression compared with injection of the control. Injection of MV GM-CSF further enhanced the oncolytic effect. In additional experiments, the cellular response to MV, MV GM-CSF, recombinant murine GM-CSF alone, or untreated tumors was quantified. The predominant response was an influx of neutrophils. Intratumoral natural killer cells and macrophages were not detected. The magnitude of the neutrophil response correlated well with tumor regression. Our studies suggest that therapy with replicating MV stimulates a strong neutrophil antitumor response, which can be cytokine-enhanced to improve oncolysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559838

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.

Authors:  Aditi Dey; Yu Zhang; Anna Z Castleton; Katharine Bailey; Brendan Beaton; Bella Patel; Adele K Fielding
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

2.  Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.

Authors:  Bella Patel; Aditi Dey; Ehsan Ghorani; Shaji Kumar; Yogeshkumar Malam; Lena Rai; Andrew J Steele; Jennifer Thomson; R Gitendra Wickremasinghe; Yu Zhang; Anna Z Castleton; Adele K Fielding
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

3.  CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

Authors:  Christine E Engeland; Christian Grossardt; Rūta Veinalde; Sascha Bossow; Diana Lutz; Johanna K Kaufmann; Ivan Shevchenko; Viktor Umansky; Dirk M Nettelbeck; Wilko Weichert; Dirk Jäger; Christof von Kalle; Guy Ungerechts
Journal:  Mol Ther       Date:  2014-08-26       Impact factor: 11.454

4.  Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Authors:  Candice Willmon; Rosa M Diaz; Phonphimon Wongthida; Feorillo Galivo; Timothy Kottke; Jill Thompson; Steven Albelda; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

5.  Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin.

Authors:  Irini Bournazou; John D Pound; Rodger Duffin; Stylianos Bournazos; Lynsey A Melville; Simon B Brown; Adriano G Rossi; Christopher D Gregory
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

6.  In Vivo Estimation of Oncolytic Virus Populations within Tumors.

Authors:  Mi-Yeon Jung; Chetan P Offord; Matthew K Ennis; Iris Kemler; Claudia Neuhauser; David Dingli
Journal:  Cancer Res       Date:  2018-08-16       Impact factor: 12.701

7.  Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.

Authors:  Phonphimon Wongthida; Rosa Maria Diaz; Feorillo Galivo; Timothy Kottke; Jill Thompson; Jose Pulido; Kevin Pavelko; Larry Pease; Alan Melcher; Richard Vile
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

8.  Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Authors:  Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester
Journal:  Clin Cancer Res       Date:  2011-05-16       Impact factor: 12.531

Review 9.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

Review 10.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.